Research programme: cyplasin glycoprotein - Bioxen

Drug Profile

Research programme: cyplasin glycoprotein - Bioxen

Alternative Names: Cyplasin; Cyplasin-SC

Latest Information Update: 04 Apr 2011

Price : $50

At a glance

  • Originator Cyplasin Biomedical
  • Developer Bioxen
  • Class Glycoproteins; Recombinant proteins
  • Mechanism of Action Actin modulators; Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Malignant melanoma

Most Recent Events

  • 13 Feb 2009 Cysplasin glycoprotein licensed to Bioxen worldwide
  • 11 Jan 2008 Cyplasin Biomedical completes equity financing totalling $US1.1 million
  • 12 Oct 2007 Preclinical data added to the adverse events and Cancer pharmacodynamics sections ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top